Mechanism of the Antiplatelet Action of Dipyridamole in Whole Blood: Modulation of Adenosine Concentration and Activity

Summary

Dipyridamole inhibits platelet aggregation in whole blood at lower concentrations than in plasma. The blood cells responsible for increased effectiveness in blood are the erythrocytes. Using the impedance aggregometer we have carried out a series of pharmacological studies in vitro to elucidate the mechanism of action of dipyridamole in whole blood. Adenosine deaminase, an enzyme breaking down adenosine, reverses the inhibitory action of dipyridamole. Two different adenosine receptor antagonists, 5’-deoxy-5’-methylthioadenosine and theophylline, also partially neutralize the activity of dipyridamole in blood. Enprofylline, a phosphodiesterase inhibitor with almost no adenosine receptor antagonistic properties, potentiates the inhibition of platelet aggregation by dipyridamole. An inhibitory effect similar to that of dipyridamole can be obtained combining a pure adenosine uptake inhibitor (RE 102 BS) with a pure phosphodiesterase inhibitor (MX-MB 82 or enprofylline). Mixing the blood during preincubation with dipyridamole increases the degree of inhibition. Lowering the haematocrit slightly reduces the effectiveness.

Although we did not carry out direct measurements of adenosine levels, the results of our pharmacological studies clearly show that dipyridamole inhibits platelet aggregation in whole blood by blocking the reuptake of adenosine formed from precursors released by red blood cells following microtrauma. Its slight phosphodiesterase inhibitory action potentiates the effects of adenosine on platelets.

Key words

Adenosine deaminase - Adenosine receptor antagonism - Impedance aggregometry - Phosphodiesterase inhibition - Platelet aggregation - Red blood cells

• References

• 1 Harker LA, Kadatz RA. Mechanism of action of dipyridamole. Thromb Res 1983; (Suppl. 04) 39-46
• 2 Gresele P, Zoja C, Deckmyn H, Arnout J, Vermylen J, Verstraete M. Dipyridamole inhibits platelet aggregation in whole blood. Thromb Haemostas 1983; 50: 852-856
• 3 Berne RM, Foley DH, Watkinson WP, Miller WL, Winn HR, Rubio R. Role of adenosine as a mediator of metabolic vasodilation in the heart and brain: a brief overview and update. In: Physiological and regulatory functions of adenosine and adenine nucleotides Baer HP, Drummond GI. (eds) Raven, New York: 1979: 117-126
• 4 Haslam RJ, Rosson GM. Effects of adenosine on levels of adenosine cyclic 3’,5’-monophosphate in human blood platelets in relation to adenosine incorporation and platelet aggregation. Mol Pharmacol 1975; 11: 528-544
• 5 Arch JR S, Newsholme EA. The control of the metabolism and the hormonal role of adenosine. Essays Biochem 1978; 14: 82-123
• 6 Vermylen J, Badenhorst PN, Deckmyn H, Arnout J. Normal mechanisms of platelet function. Clin Haematol 1983; 12: 107-151
• 7 Cardinal DC, Flower RJ. The electronic aggregometer: a novel device for assessing platelet behavior in blood. J Pharmacol Meth 1980; 3: 135-158
• 8 Born GV R, Cross MJ. The aggregation of blood platelets. J Physiol 1963; 168: 178-195
• 9 Lewis GP. Method using ortho-tolidine for the quantitative determination of haemoglobin in serum and urine. J Clin Pathol 1965; 18: 235-239
• 10 Bruns RF. Adenosine receptor activation in human fibroblasts: nucleoside agonists and antagonists. Can J Physiol Pharmacol 1980; 58: 673-691
• 11 Agarwal KC, Parks RE. 5’-methylthioadenosine and 2’,5’-dideoxy-adenosine blockade of the inhibitory effects of adenosine on ADP-induced platelet aggregation by different mechanisms. Biochem Pharmacol 1980; 29: 2529-2532
• 12 Fredholm BB. Are methylxanthine effects due to antagonism of endogenous adenosine. Trends Pharmacol Sci 1980; 1: 129-132
• 13 Vinge E, Andersson KE, Persson CG A. Effects on aggregation of human platelets of two xanthines and their interactions with adenosine. Acta Physiol Scand 1984; 120: 117-121
• 14 Mills DC B, Smith JB. The influence on platelet aggregation of drugs . that affect the accumulation of adenosine 3’,5’-cyclic monophosphate in platelets. Biochem J 1971; 121: 185-196
• 15 Lunell E, Svedmyr N, Andersson KE, Persson CG A. Effects of enprofylline, a xanthine lacking adenosine receptor antagonism, in patients with chronic obstructive lung disease. Eur J Clin Pharmacol 1982; 22: 395-402
• 16 Gaddum JH. Pharmacology, 5th ed, p 504. Oxford University Press, London 1959
• 17 Daly JW. Adenosine receptors: targets for future drugs. J Med Chem 1982; 25: 197-207
• 18 Agarwal RP, Spector T, Parks RE. Tight-binding inhibitors. IV. Inhibition of adenosine deaminases by various inhibitors. Biochem Pharmacol 1977; 26: 359-367
• 19 Holme S, Sixma JJ, Webster J, Holmsen H. ADP-induced refractory state of platelets in vitro. II. Functional and ultra studies on gel filtered platelets. Scand J Haematol 1977; 18: 267-278
• 20 Gorman RR, Bunting S, Miller OV. Modulation of human platelet adenylate cyclase by prostacyclin (PGX). Prostaglandins 1977; 13: 377-388
• 21 Azuma H, Takashima Y, Ishikawa M, Yamakado T. Potentiation of antiaggregating activity of adenosine by a phosphodiesterase inhibitor, EG626 (oxagrelate), in human platelets in vitro. Japan J Pharmacol 1984; 34: 159-170
• 22 Darius H, Lefer AM, Lepran I, Smith JB. In vivo interaction of prostacyclin with an inhibitor of cyclic nucleotide phosphodiesterase, HL 725. Brit J Pharmacol 1985; 84: 735-741
• 23 Gresele P, Deckmyn H, Amout J, Vermylen J. Platelet inhibitory activity of prostacyclin in the presence of erythrocytes as studied with the impedance aggregometer. Brit J Haematol 1984; 57: 171-173
• 24 Gresele P, Arnout J, Deckmyn H, Vermylen J. Combining antiplatelet agents: potentiation between aspirin and dipyridamole. Lancet 1985; 1: 937-938
• 25 Defreyn G, Deckmyn H, Vermylen J. A thromboxane synthetase inhibitor reorients endoperoxide metabolism in whole blood towards prostacyclin and prostaglandin E₂ . Thromb Res 1982; 26: 389-400
• 26 Rybicky JP, Le Breton GC. Prostaglandin H₂ directly lowers human platelet cAMP levels. Thromb Res 1983; 30: 407-414
• 27 Klabunde RE. Dipyridamole inhibition of adenosine metabolism in human blood. Eur J Pharmacol 1983; 93: 21-26
• 28 Sollevi A, Ostergren J, Fagrell B, Hjemdahl P. Theophylline antagonizes cardiovascular responses to dipyridamole in man without affecting increases in plasma adenosine. Acta Physiol Scand 1984; 121: 165-171
• 29 Aursnes I, Gjesdal K, Abildgaard U. Platelet aggregation induced by ADP from unsheared erythrocytes at physiological Ca⁺⁺ concentration. Brit J Haematol 1981; 47: 149-152
• 30 Saniabadi AR, Lowe GD O, Barbenel JC, Forbes CD. Further studies on the role of red blood cells in spontaneous platelet aggregation. Thromb Res 1985; 38: 225-232
• 31 Sullivan JM, Harken DE, Gorlin R. Pharmacologic control of thromboembolic complications of cardiac-valve replacement. N Engl J Med 1971; 284: 1391-1394
• 32 Newby AC. Adenosine and the concept of “retaliatory metabolites”. Trend Biochem Sci 1984; 9: 42-44
• 33 Nenci GG, Berrettini M, Todisco T, Parise P. Enhanced plasma P-thromboglobulin in hypoxemia: effect of dipyridamole. N Engl J Med 1981; 304: 1044
• 34 Tremoli E, Bertoli L, Merlini R, Colli S, Maderna P, Mantero O, Sirtori CR. Dipyridamole treatment in chronic obstructive airways disease: effect on platelet regeneration time. Eur J Clin Pharmacol 1982; 23: 423-427
• 35 Vanderwel M, Hrbolich JK, Haslam RJ. Dipyridamole increases platelet cAMP in rabbit whole blood in vivo and in vitro. Thromb Haemostas 1985 54. 183 (Abstr)
• 36 Dawicki DD, Agarwal KC, Parks RE. Role of adenosine uptake and metabolism by blood cells in the antiplatelet actions of dipyridamole, dilazep and nitrobenzylthioinosine. Biochem Pharmacol 1985; 34: 3965-3972